View clinical trials related to Neoplasms.
Filter by:Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.
This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
The objective of this observational study is to introduce a patient navigation system within the breast cancer unit at Hospital Central de Maputo (MOZ) and gather data to assess the efficacy of patient navigation in enhancing oncological outcomes among this patient cohort. The primary inquiries it seeks to address are as follows: - Can patient navigation reduce the duration (in days) between patient admission and the commencement of treatment? - Does patient navigation influence overall survival rates when juxtaposed with historical cohorts from the local setting? Participants will receive continuous support from a patient navigator starting from admission until the initiation of any oncological treatment.
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
Cancer treatment in children is very effective, but unfortunately has side effects - unwanted, bad impact. Some drugs that are given during cancer treatment, in addition to their good effect, can affect the heart badly and can lower the physical activity tolerance, such as climbing stairs, fast walking, running, exercise. Physical activity is very important for the proper growth and development of children and future adults. Heart is an important organ pumping the blood around the body and its good function is one of the key determinants of physical activity level in humans. The goal of this study is to is to find what impacts physical activity level in children treated for cancer with treatment methods that may be toxic to the heart to learn about influence of this treatment on the physical activity level of these children. The main questions this study aims to answer are: - Do children after cancer treatment involving heart toxic treatment methods present lower level of daily physical activity in comparison to the children treated with different methods? - Is the level of physical activity related to the heart toxic treatment, or other such as exercise capacity (measured physical strength on the treadmill or standing bike), quality of life, lifestyle, social and demographic factors, body type as well as the knowledge about positive impact of physical activity, efficacy, and motivation to physical activity? Participants will: - fill in the questionnaire, - perform an exercise test on the treadmill or standing bike (to measure exercise capacity), - perform ALPHA test (physical fitness test) consisting of some simple exercise like jumping, running etc., - be measured and weighted, - be measured by the hand-grip test with the hand dynamometer machine, - wear activity-tracker band for 14 days, - be examined by the ultrasound of the heart (echocardiography). Researchers will compare 144 children treated with heart toxic methods for cancer to 144 children treated for cancer with non-toxic methods. The children will be aged 8-18 years old and will be 1-5 years after treatment for cancer. The researchers believe that finding what influences physical activity level in children after cancer treatment with heart toxic methods may - make the therapy for cancer in children better, with less side effects - by that, can cause increase in the physical activity and ensure better growth and health for these children in the future.
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, as monotherapy or in combination with fulvestrant, letrozole, or other combination partners in Chinese participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced or metastatic solid tumors.